Martin Gotthardt
Overview
Explore the profile of Martin Gotthardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
2647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tokgoz S, Boss M, Jansen T, Jansen T, Meijer R, Frielink C, et al.
Diabetes
. 2024 Nov;
74(2):212-222.
PMID: 39561332
It is unclear why some individuals with type 2 diabetes are unresponsive to treatment with glucagon-like peptide 1 receptor (GLP-1R) agonists, but hypothalamic-pituitary-adrenal (HPA) axis activation could play a role....
2.
Boss M, Eriksson O, Mikkola K, Eek A, Brom M, Buitinga M, et al.
J Nucl Med
. 2024 Oct;
65(12):1959-1964.
PMID: 39419553
Precise anatomic localization of insulinomas is crucial for surgical treatment. Current routine noninvasive imaging techniques, including CT, MRI, and Ga-DOTA-somatostatin analog (DOTA-SSA) PET/CT, have limited sensitivity. Endoscopic ultrasound is highly...
3.
Jansen T, Tokgoz S, Buitinga M, van Lith S, Joosten L, Frielink C, et al.
EJNMMI Res
. 2024 Oct;
14(1):96.
PMID: 39405026
Background: Estimation of beta cell mass is currently restricted to evaluating pancreatic tissue samples, which provides limited information. A non-invasive imaging technique that reliably quantifies beta cell mass enables monitoring...
4.
Michelotti F, Bowden G, Eter W, Kuppers A, Maurer A, Nischwitz V, et al.
Nucl Med Biol
. 2024 Oct;
138-139:108962.
PMID: 39393206
Purpose: Monitoring β-cell mass and function would provide a better understanding of diabetes, setting the stage for truly individualized therapies. We applied a combined PET/MRI protocol to monitor engrafted islets...
5.
Prive B, Muselaers C, van Oort I, Janssen M, Peters S, van Gemert W, et al.
Front Nucl Med
. 2024 Oct;
2:863101.
PMID: 39354959
Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen...
6.
van Ruitenbeek N, Uijen M, Driessen C, Peters S, Prive B, van Engen-van Grunsven A, et al.
Theranostics
. 2024 Sep;
14(14):5388-5399.
PMID: 39310108
There is an urgent need for novel systemic therapies for recurrent/systemic salivary gland cancer, as current treatment options are scarce. [Ga]Ga-PSMA-11 PET/CT revealed relevant uptake of prostate-specific membrane antigen (PSMA)...
7.
Bormans E, Schuurs-Hoeijmakers J, van Setten P, Hendricks L, Drissen M, Gotthardt M, et al.
J Clin Res Pediatr Endocrinol
. 2024 Aug;
PMID: 39113393
Objective: Children with PTEN hamartoma tumor syndrome (PHTS) are at increased risk for developing thyroid abnormalities, including differentiated thyroid carcinoma (DTC). The Dutch PHTS guideline recommends ultrasound surveillance starting from...
8.
Smeets E, Trajkovic-Arsic M, Geijs D, Karakaya S, van Zanten M, Brosens L, et al.
J Nucl Med
. 2024 May;
65(7):1151-1159.
PMID: 38782455
Radiomics features can reveal hidden patterns in a tumor but usually lack an underlying biologic rationale. In this work, we aimed to investigate whether there is a correlation between radiomics...
9.
Prive B, Israel B, Janssen M, van der Leest M, de Rooij M, van Ipenburg J, et al.
Radiology
. 2024 May;
311(2):e231879.
PMID: 38771185
Background Multiparametric MRI (mpMRI) is effective for detecting prostate cancer (PCa); however, there is a high rate of equivocal Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions and false-positive...
10.
Bol K, Schreibelt G, Bloemendal M, van Willigen W, Hins-de Bree S, de Goede A, et al.
Nat Commun
. 2024 Feb;
15(1):1632.
PMID: 38395969
Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C...